Test-and-treat: The end of the HIV epidemic?

Current Opinion in Infectious Diseases

Volumn 24, Issue 1, 2011, Pages 19-26

  Cambiano, Valentina ^a   Rodger, Alison J ^a   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

antiretroviral therapy; HIV test; prevention; test and treat

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; EPIDEMIC; FEASIBILITY STUDY; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE HOMOSEXUAL; MATHEMATICAL MODEL; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; VIRUS INFECTIVITY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, INFECTIOUS; HIV INFECTIONS; HIV-1; HUMANS; PANDEMICS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78751572916     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283422c8c     Document Type: Article

References (110)

1. UNAIDS. AIDS epidemic update: November 2009. Geneva: UNAIDS, World Health Organization; 2010.
2. Bailey RC, Moses S, Parker CB, etal. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-656.
3. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657-666.
4. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:1112-1122.
5. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
6. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-2567.
7. Vernazza PL, Troiani L, Flepp MJ, etal. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121.
8. AttiaS, Egger M, Muller M, etal. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
9. Bunnell R, Ekwaru JP, Solberg P, etal. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92.
10. Castilla J, Del RJ, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
11. Del Romero J, Castilla J, Hernando V, etal. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. Br Med J 2010; 340:c2205.
12. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
13. Hardy AM, Allen JR, Morgan WM, Curran JW. The incidence rate of acquired immunodeficiency syndrome in selected populations. JAMA 1985; 253: 215-220.
14. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2:403-407.
15. Kingsley LA, Detels R, Kaslow R, et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet 1987; 1:345-349. (Pubitemid 17010021)
16. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-1078.
17. De Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331:341-346.
18. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
19. WawerMJ,Gray RH,SewankamboNK, etal. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
20. Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-1792.
21. Li JJ, Liu Y, KimT, etal. Gene expression variability within and between human populations and implications toward disease susceptibility. PLoS Comput Biol 2010; 6:e1000910.
22. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
23. Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314-320.
24. Centers for Disease Control and Prevention. Missed opportunities for earlier diagnosis of HIV infection-South Carolina, 1997-2005. MMWR Morb Mortal Wkly Rep 2006; 55:1269-1272.
25. Fox J, White PJ, Macdonald N, et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 2009; 10:432-438.
26. Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early HIV infection - a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav 2009; 13:1054-1060.
27. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
28. Miiro G, Todd J, Mpendo J, et al. Reduced morbidity and mortality in the first year after initiating highly active antiretroviral therapy (HAART) among Ugandan adults. Trop Med Int Health 2009; 14:556-563.
29. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454.
30. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371:1603-1611.
31. Egger M, Hirschel B, Francioli P, etal. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997; 315:1194-1199.
32. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
33. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421.
34. Kotler DP, Shimada T, Snow G, et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apop-tosis. AIDS 1998; 12:597-604.
35. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 2009; 373:9-11.
36. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-735.
37. RuarkA, Shelton JD, Halperin DT, etal. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1078.
38. Jurgens R, Cohen J, Tarantola D, et al. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1079.
39. Walensky RP, Paltiel AD, Losina E, et al. Test and Treat DC: forecasting the impact of a comprehensive HIV Strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.
40. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
41. Guay LA, Musoke P, Fleming T, etal. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
42. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-1182.
43. Fang CT, Hsu HM, Twu SJ, etal. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
44. Porco TC, Martin JN, Page-Shafer KA, etal. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88.
45. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
46. Wang L, Ge Z, Luo J, et al. HIV Transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 2010; 55:232-238.
47. HIV Prevention Trials Network. HPTN 052: a randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in serodiscordant couples. 2005. http://clinicaltrials.gov/ct2/show/NCT00074581? term=hptn052&rank=1 ClinicalTrials.gov. Identifier: NCT00074581 [accessed 16 November 2010].
48. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:1-5.
49. Wood E, Kerr T, Marshall BD, etal. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. Br Med J 2009; 338:b1649.
50. Katz MH, Schwarcz SK, Kellogg TA, etal. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-394.
51. Dukers NH, Spaargaren J, Geskus RB, etal. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 2002; 16:F19-F24.
52. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. 2009. http://www.who.int/hiv/pub/2009progressreport/ en/index.html. [accessed 16 November 2010].
53. Bunnell R, Mermin J, De Cock KM. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA 2006; 296:855-858.
54. Evans HE, Mercer CH, Rait G, et al. Trends in HIV testing and recording of HIV status in the UK primary care setting: a retrospective cohort study 1995-2005. Sex Transm Infect 2009; 85:520-526.
55. Health Protection Agency. HIV in the United Kingdom: 2009 report; 2009. London: Health Protection Agency; 2009. http://www.hpa.org.uk/web/HPA-webFile/ HPAweb-C/1259151891830.
56. British HIV Association. British Association of Sexual Health and HIV British Infection Society. UK National Guidelines for HIV testing 2008. 2008. http:// www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf [accessed 16 November 2010].
57. Kaiser Family Foundation's. HIV testing in the United States. 2010. Park (CA): Kaiser Family Foundation's, 2010 June. http://www.kff.org/hivaids/ upload/6094-10.pdf [accessed 16 November 2010].
58. Centers for Disease Control and Prevention. New estimates of US. HIV Prevalence, 2006. Atlanta: Centers for Disease Control and Prevention 2008. http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/ pdf/prevalence.pdf [accessed 16 November 2010].
59. Sabin CA, SchwenkA, Johnson MA, etal. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010; 24:723-727.
60. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 2009; 21:284-293.
61. Klein D, Hurley LB, Merrill D, Quesenberry CP Jr. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003; 32:143-152.
62. Dowling T. Rapid HIV testing among racial/ethnic minority men at gay pride events-nine US cities, 2004-2006. MMWR 2007; Report No. 56(24).
63. Liddicoat RV, Horton NJ, Urban R, et al. Assessing missed opportunities for HIV testing in medical settings. J Gen Intern Med 2004; 19:349-356.
64. HPTN 065:TLC-Plus: a study to evaluate the feasibility of an enhanced test, link to care, plus treat approach for HIV prevention in the United States. 2010. http://clinicaltrials.gov/ct2/show/NCT01152918?term=HPTN+065&rank= 1ClinicalTrials.gov. Identifier: NCT01152918 [accessed 16 November 2010].
65. Stephenson J. Scientists explore use of anti-HIV drugs as a means to slow HIV transmission. JAMA 2010; 303:1798-1799.
66. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536.
67. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
68. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
69. Strategic Timing of antiretroviral treatment (START). 2010. http://clinicaltrials.gov/ct2/show/NCT00867048?term=start&rank=1. ClinicalTrials.gov. Identifier: NCT00867048 [accessed 16 November 2010].
70. Cambiano V, Lampe FC, Rodger AJ, et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV infected individuals with viral suppression. HIV Med 2009; 11:216-224.
71. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-829.
72. Sungkanuparph S, Overton ET, Seyfried W, et al. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-tran- scriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41:1326-1332.
73. Pereira AS, Kashuba AD, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999; 180:2039-2043.
74. Coombs RW, Speck CE, Hughes JP, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998; 177:320-330.
75. Min SS, Corbett AH, Rezk N, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004; 37:1577-1580.
76. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18:1958-1961.
77. Smith RJ, Okano JT, Kahn JS, et al. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of san francisco. Science 2010; 327:697-701.
78. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654.
79. Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? AIDS 2010; 24:775-776.
80. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493.
81. Kalichman SC, Cherry C, Amaral CM, et al. Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat ap proaches to HIV prevention. AIDS Patient Care STDS 2010; 24:271-277.
82. Law MG, Prestage G, Grulich A, et al. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294.
83. Hayden EC. 'Seek, test and treat' slows HIV. Nature 2010; 463:1006.
84. Phillips AN, Pillay D, Bennet D, etal. Predicted effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first-to second-line antiretroviral regimens in resource-limited settings. In 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February, 2010; San Francisco, CA. 2010; abstract 596.
85. Salomon JA, Hogan DR, Stover J, et al. Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2005; 2:50-56.
86. Boily MC, Bastos FI, Desai K, Masse B. Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models. Sex Transm Dis 2004; 31:100-113.
87. Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 2003; 17:1941-1951.
88. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr 2006; 41:632-641.
89. Diabate S, Alary M, Koffi CK. Short-term increase in unsafe sexual behaviour after initiation of HAART in Cote d'Ivoire. AIDS 2008; 22:154-156.
90. Marshall BDL, Milloy MJ, Kerr T, et al. No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs. AIDS 2010; 24:2271-2278.
91. Peltzer K, Ramlagan S. Safer sexual behaviours after 1 year of antiretroviral treatment in KwaZulu-Natal, South Africa: a prospective cohort study. Sexual Health 2010; 7:135-141.
92. Kennedy C, O'Reilly K, Medley A, Sweat M. The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 2007; 19:707-720.
93. Sarna A, Luchters SMF, Geibel S, et al. Sexual risk behaviour and HAART: a comparative study of HIV-infected persons on HAART and on preventive therapy in Kenya. Int J STD AIDS 2008; 19:85-89.
94. Moatti JP, Prudhomme J, Traore DC, et al. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Cote d'Ivoire. AIDS 2003; 17:S69-S77.
95. Stephenson JM, Imrie J, Davis MMD, et al. Is use of antiretroviral therapy among homosexual men associated with increased risk of transmission of HIV infection? Sex Transm Infect 2003; 79:7-10.
96. EiseleTP, Mathews C, Chopra M, et al. Changes in risk behavior among HIV-positive patients during their first year of antiretroviral therapy in Cape Town South Africa. AIDS Behav 2009; 13:1097-1105.
97. McClelland RS, Graham SM, Richardson BA, et al. Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS 2010; 24:891-897.
98. Bechange S, Bunnell R, Awor A, et al. Two-year follow-up of sexual behavior among HIV-uninfected household members of adults taking antiretroviral therapy in Uganda: no evidence of disinhibition. AIDS Behav 2010; 14:816-823.
99. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 2003; 79:59-61.
100. Burman W, Grund B, NeuhausJ, etal. Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. J Acquir Immune Defic Syndr 2008; 49:142-150.
101. Bunnell R, Opio A, Musinguzi J, et al. HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS 2008; 22:617-624.
102. Elford J. Changing patterns of sexual behaviour in the era of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19:26-32.
103. Stolte IG, Dukers NHTM, Geskus RB, et al. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 2004; 18:303-309.
104. Balthasar H, Jeannin A, Dubois-Arber F. Surveillance of HIV/AIDS-related behaviors among men who have sex with men: Switzerland, 1992-2004. Int J Public Health 2007; 52:27-38.
105. SulliVan PS, Drake AJ, Sanchez TH. Prevalence of treatment optimism-related risk behavior and associated factors among men who have sex with men in 11 states, 2000-2001. AIDS Behav 2007; 11:123-129.
106. Crepaz N, Marks G, Liau A, etal. Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis. AIDS 2009; 23:1617-1629.
107. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7:1016-1020.
108. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59-67.
109. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmis sion: a mathematical model. Lancet 2009; 373:48-57.
110. Epstein H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1078-1079.